Impact of GLP-1 Receptor Agonists on Body Composition and Physical Performance in Patients with Obesity: A Comprehensive Review of Current Research
DOI:
https://doi.org/10.12775/QS.2026.51.68929Keywords
GLP-1 receptor agonists, obesity, body composition, lean mass, physical performance, functional capacity, sarcopeniaAbstract
Background.
GLP-1 receptor agonists (GLP-1RAs) are central to obesity pharmacotherapy, producing substantial and sustained weight loss in randomized trials, with additional cardiometabolic benefits. Growing attention concerns their effects on body composition, particularly fat versus lean mass loss, and potential impacts on skeletal muscle function and physical performance. These outcomes are highly relevant to sports medicine and rehabilitation, where muscle preservation is crucial.
Aim.
To review evidence on the effects of GLP-1RAs on body composition and physical performance in adults with obesity, focusing on fat mass, lean mass and populations at risk of muscle-related adverse effects.
Materials and methods.
Narrative review of 30 PubMed-indexed studies (2015–2026), including RCTs, DXA substudies and reviews of liraglutide, semaglutide and tirzepatide in adults with overweight/obesity.
Results.
GLP-1RAs consistently reduced body weight and fat mass, with 15–40% of weight loss attributable to lean mass reduction. Semaglutide improved physical function and exercise tolerance in obesity-related functional impairment and HFpEF, while potential sarcopenic effects were reported in older adults and those with low baseline muscle mass. Reviews highlight heterogeneity of lean mass responses and the importance of lifestyle interventions.
Conclusions.
GLP-1RAs induce major fat loss but are associated with clinically relevant lean mass loss. Combining pharmacotherapy with exercise and nutrition is essential to optimize body composition and physical performance.
References
1. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183
2. Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1414-1425. doi:10.1001/jama.2021.3224
3. Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021;325(14):1403-1413. doi:10.1001/jama.2021.1831
4. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083-2091. doi:10.1038/s41591-022-02026-4.
5. Rubino DM, Greenway FL, Khalid U, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022;327(2):138-150. doi:10.1001/jama.2021.23619
6. Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971-984. doi:10.1016/S0140-6736(21)00213-0
7. Weghuber D, Barrett T, Barrientos-Pérez M, et al. Once-Weekly Semaglutide in Adolescents with Obesity. N Engl J Med. 2022;387(24):2245-2257. doi:10.1056/NEJMoa2208601
8. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038
9. Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402(10402):613-626. doi:10.1016/S0140-6736(23)01200-X
10. Wadden TA, Chao AM, Machineni S, et al. Author Correction: Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med. 2024;30(6):1784. doi:10.1038/s41591-024-02883-1
11. Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48. doi:10.1001/jama.2023.24945
12. Jastreboff AM, le Roux CW, Stefanski A, et al. Tirzepatide for Obesity Treatment and Diabetes Prevention. N Engl J Med. 2025;392(10):958-971. doi:10.1056/NEJMoa2410819
13. Look M, Dunn JP, Kushner RF, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025;27(5):2720-2729. doi:10.1111/dom.16275
14. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563
15. Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023;389(12):1069-1084. doi:10.1056/NEJMoa2306963
16. Borlaug, B.A., Kitzman, D.W., Davies, M.J. et al. Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial. Nat Med 29, 2358–2365 (2023). https://doi.org/10.1038/s41591-023-02526-x
17. Kosiborod MN, Petrie MC, Borlaug BA, et al. Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes. N Engl J Med. 2024;390(15):1394-1407. doi:10.1056/NEJMoa2313917
18. Butler, J, Abildstrøm, S, Borlaug, B. et al. Semaglutide in Patients With Obesity and Heart Failure Across Mildly Reduced or Preserved Ejection Fraction. JACC. 2023 Nov, 82 (22) 2087–2096.
https://doi.org/10.1016/j.jacc.2023.09.811
19. Kosiborod MN, Verma S, Borlaug BA, et al. Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial. Circulation. 2024;149(3):204-216. doi:10.1161/CIRCULATIONAHA.123.067505
20. Cortes TM, Vasquez L, Serra MC, et al. Effect of Semaglutide on Physical Function, Body Composition, and Biomarkers of Aging in Older Adults With Overweight and Insulin Resistance: Protocol for an Open-Labeled Randomized Controlled Trial. JMIR Res Protoc. 2024;13:e62667. Published 2024 Sep 13. doi:10.2196/62667
21. McCrimmon RJ, Catarig AM, Frias JP, et al. Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial. Diabetologia. 2020;63(3):473-485. doi:10.1007/s00125-019-05065-8
22. Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22. doi:10.1056/NEJMoa1411892
23. Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond). 2013;37(11):1443-1451. doi:10.1038/ijo.2013.120
24. Blackman A, Foster GD, Zammit G, et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. Int J Obes (Lond). 2016;40(8):1310-1319. doi:10.1038/ijo.2016.52
25. Lu J, Zou S, Liu X, et al. The effects of GLP-1 receptor agonists on body composition in patients with type 2 diabetes, overweight or obesity: A meta-analysis of randomized controlled trials. Eur J Pharmacol. 2025;1003:177885. doi:10.1016/j.ejphar.2025.177885
26. Bikou A, Dermiki-Gkana F, Penteris M, Constantinides TK, Kontogiorgis C. A systematic review of the effect of semaglutide on lean mass: insights from clinical trials. Expert Opin Pharmacother. 2024;25(5):611-619. doi:10.1080/14656566.2024.2343092
27. Neeland IJ, Linge J, Birkenfeld AL. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes Metab. 2024;26 Suppl 4:16-27. doi:10.1111/dom.15728
28. Karakasis P, Patoulias D, Fragakis N, Mantzoros CS. Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis. Metabolism. 2025;164:156113. doi:10.1016/j.metabol.2024.156113
29. Alissou M, Demangeat T, Folope V, et al. Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study. Diabetes Obes Metab. 2026;28(1):112-121. doi:10.1111/dom.70141
30. Jiao R, Lin C, Cai X, et al. Characterizing body composition modifying effects of a glucagon-like peptide 1 receptor-based agonist: A meta-analysis. Diabetes Obes Metab. 2025;27(1):259-267. doi:10.1111/dom.16012
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Konrad Turczynowski, Kamil Turczynowski, Jakub Lichoń , Paweł Kuna , Wojciech Kuna , Jakub Pietrucha, Mateusz Gołdyn, Jakub Niski , Anna Rutkowska, Dawid Studziński
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 16
Number of citations: 0
